Generated by AI
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.
Website5858 Horton Street
EmeryVille, CA, 94608
United States
The latest articles about ESLA.
Detailed price information for Estrella Immunopharma Inc (ESLA-Q) from The Globe and Mail including charting and trades.
Summary of Nov 12's posts. Generated by AI.
No summary yet.
Summary of Oct 26's posts. Generated by AI.
No summary yet.
Summary of Nov 12's posts. Generated by AI.
Investors talking about ESLA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.